Health
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
MOUNTAIN VIEW, Calif., April 21, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study results and support a streamlined path to registration. TRD is estimated to affect up to 7 million adults in the Uni
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/d31941a21cfec20741b15783050f202d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/apyovmr43WcNskeuFWbjJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMQ--/https://media.zenfs.com/en/business-wire.com/d31941a21cfec20741b15783050f202d","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ueIZKEwY_zjmrhriH7xfTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY-/https://media.zenfs.com/en/business-wire.com/d31941a21cfec20741b15783050f202d","width":1200,"height":388}},"lazy":false},{"type":"text","content":"— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies —","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"— Trial design and MADRS primary endpoint aligned with FDA standards in depression, potentially supporting a single Phase 3 registrational pathway —","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"— Prior Phase 2a demonstrated robust antidepressant effects of ALTO-207 and favorable tolerability —","length":100,"tagName":"p","attribs":{}},{"type":"text","content":"— Topline data expected in 2H 2027 —","length":36,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., April 21, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study results and support a streamlined path to registration. TRD is estimated to affect up to 7 million adults in the United States, representing patients who do not respond adequately to current antidepressant therapies.","length":617,"tagName":"p"},{"type":"text","content":""We are excited to be initiating this Phase 2b trial, which builds on one of the strongest efficacy signals observed in treatment-resistant depression," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "AL...